AC Immune SA (ACIU)
2.50
-0.05
(-1.96%)
USD |
NASDAQ |
Oct 09, 16:00
2.51
+0.01
(+0.40%)
After-Hours: 20:00
AC Immune Enterprise Value : 139.41M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 139.41M |
| October 08, 2026 | 143.97M |
| October 07, 2026 | 145.79M |
| October 06, 2026 | 141.24M |
| October 05, 2026 | 158.55M |
| October 02, 2026 | 159.91M |
| October 01, 2026 | 167.66M |
| September 30, 2026 | 150.35M |
| September 29, 2026 | 148.52M |
| September 28, 2026 | 149.44M |
| September 25, 2026 | 141.24M |
| September 24, 2026 | 153.99M |
| September 23, 2026 | 169.48M |
| September 22, 2026 | 160.37M |
| September 21, 2026 | 153.53M |
| September 18, 2026 | 151.26M |
| September 17, 2026 | 155.81M |
| September 16, 2026 | 153.08M |
| September 15, 2026 | 155.81M |
| September 14, 2026 | 153.99M |
| September 11, 2026 | 163.10M |
| September 10, 2026 | 156.72M |
| September 09, 2026 | 163.10M |
| September 08, 2026 | 164.92M |
| September 04, 2026 | 172.21M |
| Date | Value |
|---|---|
| September 03, 2026 | 178.59M |
| September 02, 2026 | 170.39M |
| September 01, 2026 | 155.81M |
| August 31, 2026 | 152.17M |
| August 28, 2026 | 153.08M |
| August 27, 2026 | 158.55M |
| August 26, 2026 | 171.30M |
| August 25, 2026 | 177.68M |
| August 24, 2026 | 172.21M |
| August 21, 2026 | 175.85M |
| August 20, 2026 | 152.17M |
| August 19, 2026 | 146.70M |
| August 18, 2026 | 145.79M |
| August 17, 2026 | 142.15M |
| August 14, 2026 | 138.50M |
| August 13, 2026 | 145.79M |
| August 12, 2026 | 150.35M |
| August 11, 2026 | 143.06M |
| August 10, 2026 | 119.37M |
| August 07, 2026 | 126.66M |
| August 06, 2026 | 123.02M |
| August 05, 2026 | 120.28M |
| August 04, 2026 | 118.46M |
| August 03, 2026 | 113.91M |
| July 31, 2026 | 111.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Precigen, Inc. | 2.856B |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| Aldeyra Therapeutics, Inc. | 10.33M |
| BeOne Medicines Ltd. | 33.72B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.371M |
| Revenue (Quarterly) | 19.12M |
| Total Expenses (Quarterly) | 16.75M |
| EPS Diluted (Quarterly) | 0.026 |
| Profit Margin (Quarterly) | 12.40% |
| Earnings Yield | -22.24% |
| Normalized Earnings Yield | -22.08 |